Figure 6

Tissue homogenate TFV-DP mole fractions, x(TFV-DP), and mole fraction distributions are different across anatomic compartments following TAF administration (IV and implant) in C57BL/6 J mice. (A) IV TAF dosing study; a Kruskal–Wallis test (unpaired, nonparametric) was used to compare all four groups and found that the x(TFV-DP) values were significantly different (P < 0.0001). The vaginal versus rectal (P = 0.0001, ***) TFV-DP mole fractions and the spleen versus rectal (P = 0.0468, *) TFV-DP mole fractions were found to be significantly different using a Mann–Whitney t-test (unpaired, nonparametric). The thymus versus spleen (P = 0.0755) and thymus versus rectal (P = 0.6501) TFV-DP mole fractions were found to be not significantly different using the same t-test. (B) Scatter plot showing distributions of dermal x(TFV-DP) values for low- (0.28 mg d^-1 in vivo) and high- (0.58 mg d^-1 in vivo) releasing TAF implant groups; circles represent individual measurements/animals and horizontal lines represent medians. The data were not found to be significantly different (P = 0.9349) using a Mann–Whitney t-test. (C) Scatter plot showing distributions of spleen x(TFV-DP) values for IV dosing and low- (0.27 mg d^-1 in vivo) releasing TAF implant groups; circles represent individual measurements/animals and horizontal lines represent medians. The data were not found to be significantly different (P = 0.2803) using a Mann–Whitney t-test. (D) Scatter plot showing distributions of thymus x(TFV-DP) values for IV dosing and low- (0.27 mg d^-1 in vivo) releasing TAF implant groups; circles represent individual measurements/animals and horizontal lines represent medians. The data were found to be significantly different (P = 0.0257) using a Mann–Whitney t-test.